Axsome Therapeutics Inc

NASDAQ:AXSM   4:00:00 PM EDT
74.74
+17.92 (+31.54%)
5:35:38 PM EDT: $74.79 +0.05 (+0.07%)
Products

Axsome Therapeutics Announces Plans To Resubmit AXS-07 NDA Based On Successful FDA Type A Meeting

Published: 09/29/2022 11:45 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Announces Plans to Resubmit Axs-07 NDA Based on Successful FDA Type a Meeting.
Axsome Therapeutics Inc - Intends to Resubmit Its New Drug Application (nda) for Axs-07 for Acute Treatment of Migraine in Q3 of 2023.
Axsome Therapeutics Inc - No Additional Clinical Efficacy Or Safety Trials Have Been Requested by FDA for Resubmission of NDA.